Anas Safadi, MD
Cardiovascular Disease · Hobart, INNPI 1457452484
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $203,295 of the $295,123 with a category attached, or 68.9%. 60 manufacturers reported payments, led by Boston Scientific at 37.5% of the total. Reporting peaked in 2019 at $67,924 and has fallen 60.3% since, to $26,948 in 2025. Among cardiovascular disease clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,135 payments — averaging $260.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$111K
- EKOS Corporation$43K
- Medtronic$41K
- Johnson & Johnson$36K
- Philips North America LLC$35K
- Bard Peripheral Vascular, Inc.$7K
- plus $23K from 54 others
Across 19 payments — averaging $997.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$8K
- Abbott$8K
- EKOS Corporation$3K
What the payments were for
- Consulting fees$29,71010%
- Speaking & faculty fees$203,29569%
- Travel & lodging$32,84111%
- Food & beverage$29,13710%
- Education$930%
- Entertainment$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EKOSONIC$116,211
- Abre$37,270
- XARELTO$34,189
- IGT D Peripheral$20,546
- (9520) IGT Devices Undivided$12,935
- GENERAL VASCULAR INTERVENTION$8,791
- GENERAL - THERAPIES$6,404
- Varithena Administration Pack$5,882
- ANGIOJET$5,711
- ENROUTE Transcarotid Neuroprotection System$5,190
- VENOVO$3,900
- ENROUTE Transcarotid Stent$3,640
- FLOWTRIEVER CATHETER, S$3,073
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$1,550
- CoreValve Evolut$1,246
- Watchman$1,146
- (6554) Periph Vasc Undiv$940
- Indigo System$830
- GENERAL PAIN MANAGEMENT$806
- CT THROMBECTOMY SYSTEM KIT$716
How this compares
$295,123 in reported general payments places this provider in the 95th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 337 | $293,669 |
| XareltoRivaroxaban | 225 | $198,235 |
| EntrestoSacubitril/Valsartan | 158 | $148,656 |
| JardianceEmpagliflozin | 136 | $115,972 |
| FarxigaDapagliflozin Propanediol | 163 | $108,445 |
| OzempicSemaglutide | 103 | $103,228 |
| BrilintaTicagrelor | 123 | $67,283 |
| Repatha SureclickEvolocumab | 69 | $58,732 |
| MounjaroTirzepatide | 50 | $53,983 |
| WegovySemaglutide | 33 | $43,817 |
| VascepaIcosapent Ethyl | 47 | $18,170 |
| Praluent PenAlirocumab | 18 | $14,596 |
| VerquvoVericiguat | 16 | $10,523 |
| NexlizetBempedoic Acid/Ezetimibe | 16 | $9,608 |
| NexletolBempedoic Acid | 17 | $6,818 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $537 | $293,669337 claims |
| Johnson & JohnsonXarelto | $35,841 | $198,235225 claims |
| AstraZenecaFarxiga, Brilinta | $1,084 | $175,728286 claims |
| NovartisEntresto | $1,265 | $148,656158 claims |
| Novo NordiskOzempic, Wegovy | $308 | $147,045136 claims |
| Boehringer IngelheimJardiance | $1,005 | $115,972136 claims |
| Lilly USA, LLCMounjaro | $32 | $53,98350 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $644 | $16,42633 claims |
| MerckVerquvo | $750 | $10,52316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Hobart
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Wai LeeElkhart$321K
- Lawrence RinkBloomington$280K
- Vijay RaoIndianapolis$247K
- Steven SteinhublLafayette$247K
- Atul ChughIndianapolis$242K
- James TrippiIndianapolis$239K
- Christopher HealyIndianapolis$209K
- Douglas ShefferEvansville$138K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.